Nexavar gets fast-track designation for skin cancer
- U.S. regulators have granted fast-track designation to kidney cancer drug Nexavar for the treatment of advanced melanoma, a form of skin cancer.
Nexavar, made by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc , was approved by the U.S. Food and Drug Administration in December 2005 for the treatment of patients with advanced renal cell carcinoma.
Fast-track designation is designed to speed the review of drug compounds for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
- U.S. regulators have granted fast-track designation to kidney cancer drug Nexavar for the treatment of advanced melanoma, a form of skin cancer.
Nexavar, made by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc , was approved by the U.S. Food and Drug Administration in December 2005 for the treatment of patients with advanced renal cell carcinoma.
Fast-track designation is designed to speed the review of drug compounds for the treatment of patients with serious or life-threatening diseases where there is an unmet medical need.
posted by doublezero at
2:13 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home